Compare Equinix Inc (EQIX) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinix Inc vs Twist Bioscience Corp — how do they compare? Equinix Inc trades at $1,011.13 (market cap $101.81B), while Twist Bioscience Corp trades at $157 (market cap $10.32B). The key difference: Equinix Inc is far larger — about 9.9× Twist Bioscience Corp's market cap, and Equinix Inc pays a 2% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinix Inc for 110 Days and Twist Bioscience Corp for 27 Days on average.
| EQIX | TWST | |
|---|---|---|
Market Cap | $101.81B | $10.32B |
Volume | 442,874 | 5,894,998 |
Sector | Real Estate | Health |
52-Week High | $1.12K | $205.00 |
52-Week Low | $726.09 | $25.45 |
Typical Hold Time | 110 Days | 27 Days |
Enterprise Value | $122.94B | $10.24B |
Dividend Yield | 2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinix (EQIX) trades at $1,031.77, down 1.49% today, with strong analyst support (75% buy ratings) and a $1,250 consensus price target. The stock shows bullish technical signals with support at $1,025 and resistance at $1,042. Recent earnings show mixed results with Q2 2026 beating expectations but Q1 and Q4 2025 missing. The company maintains robust revenue growth, expanding from $7.3B in 2022 to $9.2B in 2025, with net income margins improving to 14.64%. AI-driven data center demand is accelerating growth, with Equinix planning $5B-$7B annual investments.
Outlook remains positive due to strong AI infrastructure demand and interconnection growth, though elevated valuation ratios (P/E 66.39) and significant capital expenditures pose risks. Debt levels have risen, with debt-to-asset ratio increasing to 47.13% in 2025. The upcoming Q3 2026 earnings on October 28 will be critical for validating growth trajectory amid competitive pressures.
TWST trades at $152.05, down 8.94% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $376.57 million in 2025, but profitability remains elusive with a net income margin of -31.66%. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, providing a potential growth catalyst amid ongoing losses.
The outlook is mixed; analyst consensus is bullish with a $145.20 price target, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on the company's ability to monetize its AI collaborations and achieve profitability, while downside risks include cash burn and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
